Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Rie Baba"'
Autor:
Rie Baba, Hiroki Kabata, Yoshitaka Shirasaki, Takashi Kamatani, Mai Yamagishi, Misato Irie, Risa Watanabe, Masako Matsusaka, Katsunori Masaki, Jun Miyata, Kazuyo Moro, Sotaro Uemura, Koichi Fukunaga
Publikováno v:
Journal of Allergy and Clinical Immunology: Global. 1:299-304
Autor:
Lisa M. Bramer, Robert D. Hontz, Amie J. Eisfeld, Amy C. Sims, Young-Mo Kim, Kelly G. Stratton, Carrie D. Nicora, Marina A. Gritsenko, Athena A. Schepmoes, Osamu Akasaka, Michiko Koga, Takeya Tsutsumi, Morio Nakamura, Ichiro Nakachi, Rie Baba, Hiroki Tateno, Shoji Suzuki, Hideaki Nakajima, Hideaki Kato, Kazunari Ishida, Makoto Ishii, Yoshifumi Uwamino, Keiko Mitamura, Vanessa L. Paurus, Ernesto S. Nakayasu, Isaac K. Attah, Andrew G. Letizia, Katrina M. Waters, Thomas O. Metz, Karen Corson, Yoshihiro Kawaoka, Vincent R. Gerbasi, Hiroshi Yotsuyanagi, Kiyoko Iwatsuki-Horimoto
Publikováno v:
Heliyon. 9:e13795
Autor:
Rie Baba, Akira Umeda, Masako Matsusaka, Yusuke Suzuki, Takae Tanosaki, Kenji Izuhara, Kengo Ohtsuka, Katsuhiko Kamei, Morio Nakamura, Tomoko Betsuyaku, Hiroki Kabata, Takashi Inoue, Takao Mochimaru, Soichiro Ueda, Koichiro Asano, Katsunori Masaki, Koichi Fukunaga, Hidefumi Koh, Takashi Kamatani, Fumio Sakamaki, Tsuyoshi Oguma, Koichi Sayama, Yoshitaka Oyamada
Publikováno v:
Annals of Allergy, Asthma & Immunology. 119:253-257
Some patients with severe asthma also have fungal sensitization and are considered to have severe asthma with fungal sensitization. However, there is limited information on the clinical features of SAFS.To investigate the clinical characteristics of
Autor:
Tohru Nagano, Tomio Tsukie, Masanori Fukushima, Kimiko Yoshikawa, Makoto Kinoshita, Atsuhiko Kawamoto, Kazuo Yamasaki, Minako Katayama, Nobuyuki Katakami, Yukikatsu Okada, Rie Baba, Nobuhiro Handa, Yukiko Nagata, Yutaka Furukawa, Yoshihiro Matsubara, Takayuki Asahara, Yasuyuki Fujita, Maki Shibakawa, Kaori Kuronaka, Yasuo Kurimoto
Publikováno v:
Atherosclerosis. 224:440-445
Background Our phase I/IIa clinical trial revealed that intramuscular transplantation of autologous, GCSF-mobilized CD34+ cells was safe, feasible and potentially effective at week 4 and 12 post cellular therapy in 17 patients with chronic critical l
Publikováno v:
Journal of the American College of Cardiology. 55:A157.E1469